Altnagelvin Hospital in Northern Ireland has become the first HSC Trust in the region to offer a groundbreaking genetic treatment for Motor Neurone Disease (MND) using the drug Tofersen.

Tofersen is the first new treatment for MND in over 30 years that specifically targets the SOD1 gene variation, which can slow or halt disease progression.

The drug was administered to the first patient at Altnagelvin Hospital in August, marking a significant milestone in regional healthcare.

Dr. Gavin McCluskey, a neurologist at Western Trust, highlighted the importance of this treatment and expressed optimism about its potential benefits for future patients.

The treatment involves monthly lumbar punctures, and the first patient, Conaire Quinn from Co. Down, hopes it will prolong his independence and allow more quality time with his family.

Conaire Quinn, the inaugural recipient, shared his hope that the drug will help him maintain his independence longer.

The Neurology and Research Teams at Western Trust received strong support from pharmacy and senior management to facilitate this innovative treatment.

Administered monthly via lumbar puncture, Tofersen aims to reduce the effects of the abnormal SOD1 gene, potentially decreasing nerve damage and slowing disease progression.